Eli Lilly (NYSE:LLY) has rolled out its best-selling diabetes drug Mounjaro in a new injector pen format in India, intensifying its battle with Novo Nordisk in the fast-growing GLP-1 market.
The Mounjaro Kwikpen, approved in June for six dose strengths from 2.5 mg to 15 mg, starts at ?14,000 ($160) for the lowest dose and rises to ?27,500 for the highest. Novo Nordisk's (NYSE:NVO) Wegovy, launched just days earlier in a similar format, is priced nearly in line across comparable doses.
Warning! GuruFocus has detected 4 Warning Signs with VG.
Lilly first entered India's obesity and diabetes market in March with Mounjaro vials and has already seen rapid uptake sales jumped 60% in May from April, according to Pharmarack Technologies. With both companies now offering user-friendly injector pens, competition is set to heat up in a country with more than 100 million diabetics and a rising obesity burden.
Analysts see India as a key growth market for GLP-1 drugs as lifestyle diseases climb and awareness of newer therapies expands.
This article first appeared on GuruFocus.
View Comments
Eli Lilly Fires Up GLP-1 Race in India With Mounjaro Pen Launch
Published 2 months ago
Aug 13, 2025 at 5:48 PM
Positive
Auto